Business · Markets · 13 hrs ago
CSL shares rebound as analyst sees room for further earnings growth
CSL is an Australian healthcare company and a global supplier of medicines made from donated blood plasma.
Its shares have rebounded strongly, rising to about $184.65 from a 52-week low of $90, but remain below their 52-week high of $222.47.
The company’s treatments include immunoglobulin therapies for people with immune deficiencies and other serious conditions.
The analysis expects earnings to grow steadily, while noting that higher collection and processing costs have hurt profitability.
CSL plans to roll out new plasma collection technology across its US centres by the end of 2027 as part of efforts to improve efficiency.
The analysis views the shares as a buy, but says they are no longer a bargain and that a gradual recovery is more likely.
CSL shares have rebounded strongly in recent months as investors have become more optimistic about the company’s future.
A Motley Fool AU article says the company has room to grow earnings through efficiency improvements and newer medicines.
Consensus forecasts cited in the article put earnings per share at $8.96 in FY27, rising to $10.03 in FY29.
CSL shares were trading around $184.65 on Monday, above their 52-week low but below their 52-week high.
The article’s author says CSL is still a buy, while warning that its valuation is no longer a bargain.
- Who
- CSL Ltd and its investors.
- What
- CSL shares have rebounded, and an article argues the company has scope for further earnings growth.
- When
- The shares were trading around $184.65 on Monday. The article was published on 12 October 2026.
- Where
- CSL is listed on the Australian Securities Exchange; the article refers to its US plasma collection centres.
- Why
- Investors have become more optimistic about CSL’s future. The article points to growing demand for treatments and potential efficiency improvements.
This story does not have two clearly opposing sides.
I would no longer describe that as a bargain valuation.
CSL is a buy for me
CSL announced an expanded relationship with Haemonetics, with plans to roll out its latest plasma collection technology across US collection centres by the end of 2027.
CSL shares were trading around $184.65.
- Share price
- Around $184.65 on Monday
- 52-week low
- $90
- 52-week high
- $222.47
- FY27 forecast EPS
- $8.96
- FY29 forecast EPS
- $10.03
- Technology rollout target
- By the end of 2027
Sources
Related news
Flexible management roles could help retain women leaders in Australia
Cheaper electric vehicles help curb inflation pressures in Australia
Jeweller outsourced making after years of exhausting work
Rent platforms replace card surcharges with fees and paid memberships
Adidas sues Australian fashion label White Fox over four-stripe clothing design
Firmus scraps planned Australian IPO as investors question its valuation
Sydney trader wins unfair dismissal case after hiding Singapore location
McKinsey removes Australian partner from research leadership role
Firmus pulls Australian IPO plans after investors balk at valuation
Australian shares rise as banks and miners rally
Board approves BGRE’s $250m plans for an EQ office building
